Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28032610 | 0.94 | GPR84 (0.42) | CA2MAPK1CA1PLA2G2CGPR84 | |
| SCHEMBL27829026 | 0.88 | PLA2G2C (0.45) | CA2MAPK1CA1PLA2G2CGPR84 | |
| SCHEMBL28196501 | 0.88 | TAS1R3 (0.40) | CA2MAPK1CA1 | |
| SCHEMBL28251103 | 0.84 | GPR84 (0.48) | CA2PLA2G2CGPR84FFAR1MAPT | |
| SCHEMBL13902710 | 0.82 | CA2 (0.40) | CA2MAPK1CA1PLA2G2CALDH1A1 | |
| SCHEMBL28223515 | 0.80 | MAPT (0.35) | PLA2G2CALDH1A1MAPT | |
| SCHEMBL1388452 | 0.79 | CA2 (0.48) | CA2MAPK1CA1PLA2G2CGPR84 | |
| Hydrochloric Acid SCHEMBL10822847 | 0.78 | CA2 (0.47) | CA2MAPK1CA1PLA2G2C | |
| SCHEMBL28849586 | 0.78 | TAS1R3 (0.44) | CA2MAPK1CA1GPR84 | |
| SCHEMBL28154509 | 0.77 | LMNA (0.44) | CA2CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137616-A | Antibacterial agents comprising pyrazino [2,3-b ] [1,4] oxazin-3-ones or related ring systems | 葛兰素史克知识产权开发有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-101454313-A | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2009-06-10 | — | — | CN | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| CN-100384843-C | CGRP receptor antagonists | MERCK & CO INC (US) | 2008-04-30 | — | — | CN | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CA2 3233/4885MAPK1 380/4885CA1 4464/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | CA2 3233/4885MAPK1 380/4885CA1 4464/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CA2 3233/4885MAPK1 380/4885CA1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.